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RESUMO: O transplante de órgãos se tornou parte importante da medicina moderna. O trans-
plante de intestino (ITx) foi introduzido no final da década de 1960 como um procedimento 
heróico para tratar falência do intestino. O Hospital das Clínicas da Faculdade de Medicina 
da Universidade de São Paulo foi um dos pioneiros mundiais neste procedimento. Com a 
evolução biotecnológica na medicina, o transplante de intestino emergiu na década de 1990 
como a única e permanente opção terapêutica para pacientes com falência intestinal irre-
versível.  Àquele tempo, os resultados clínicos eram, ainda, desapontadores, principalmente 
devido às altas taxas de infecção pós-operatória e rejeição do enxerto. Entretanto, houve um 
grande desenvolvimento do transplante intestinal e multivisceral graças à melhoria da terapia 
imunossupressora, ao refinamento das técnicas cirúrgicas e dos cuidados pós-transplantes. O 
objetivo deste estudo é oferecer um panorama sobre quando o ITx deve ser indicado e sobre 
como o procedimento deve ser realizado. 
DESCRITORES: Intestinos/transplante. Nutrição parenteral. Intestinos/patologia.
INTRODUCTION 
 
Organ transplantation has become a substantial part of modern medicine. Transplantation is a treatment option 
is case of organ failure such as the kidney, liver, 
heart, lung, pancreas and, recently also for intestinal 
failure. 
Intestinal transplantation (ITx) was introduced 
in the late sixties as a heroic procedure to treat 
intestinal failure. The Clinic Hospital of University 
of Sao Paulo Medical School is one of the world’s 
pioneer in this procedure. The legendary Professor 
Okumura performed in 1968 and 1969 the second 
and the third intestinal transplantation published 
in the medical literature, achieving one of the best 
survivals at that time; however, strong graft rejection 
and infection impaired the long term survival of this 
procedure34-38.
Important advances in Total Parenteral Nutrition 
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(TPN) successfully brought longer survival to intestinal 
failure patients and became the paramount treatment 
for this disease. Nevertheless, TPN promotes many 
inconveniences, such as inability to eat, catheter 
infections, metabolic and hydroelectrolytic alterations 
and dysfunction of other organs, mainly the liver. 
With the biotechnological evolution in medicine, 
intestinal transplantation emerged in the 1990s as the 
only curative, permanent therapeutic option for patients 
with irreversible intestinal failure. At that time, the clinical 
results were also disappointing mainly due to the same 
high rates of post-operative infectious complications 
and graft rejection. However, the development of 
intestinal and multivisceral transplantation has been 
profound owing to the progress in immunosuppressive 
therapy, refinement of surgical techniques, and post-
transplant care including immunological as well as 
anti-infectious monitoring1,1,2,2. This progress has 
accordingly caused substantial advancement in graft 
and patient survival (Table 1). 
TABLE 1. Graft and patient survival after transplantation
Transplant type Survival 1-year 3-year 5-year
Liver only (deceased donor only) Graft survival 82.2% 73.2% 66.9%
Patient survival 86.8% 79.1% 73.1%
Intestine only Graft survival 73.8% 46.7% 37.6%
Patient survival 85.7% 60.6% 53.5%
Liver/intestine Graft survival  65.7% 49.7% 44.1%
Patiënt survival 66.7% 56.6% 47.2%
Reprinted from Fryer JP. The current status of intestinal transplantation. Advances in Digestive Disease. Published by AGA Institute Press, 
2007.
ITx has evolved from being considered an 
experimental procedure to become a clinically 
accepted therapy, now performed in over 73 centers 
worldwide, with over 2000 transplants to date. 
The field of transplantation is not covered in the 
current medical curriculum despite a great interest and 
positive attitude of medical students towards organ 
donation and transplantation1-3. Therefore, especially 
the subject of intestinal transplantation which is a 
relatively novel transplant type - is generally unknown 
to the medical student and most specialists not directly 
involved in transplantation.  
The aim of this paper is to give a general 
overview of intestinal transplantation.
This overview will address patient population 
and indications, types of intestinal transplant 
procedures, intestinal preservation, postoperative 
care (immunosuppression, control of infection and 
nutritional approach), and outcome (complications, 
rejection and survival). Finally, specific difficulties and 
future perspectives will be discussed.  
Experimental bases
The first reported small bowel transplantation 
was performed by Lillehei et al.39 fifty year ago on 
dogs. In 1960, Starzl and Kaupp40 described the 
first experimental observations of multivisceral 
transplantation, also on dogs. In 1972, Monchick and 
Russel41described the first microsurgical technique for 
intestinal transplantation on rats. Due to the genetic 
possibility, low cost and praticity, the rat became 
the best model to perform research on intestinal 
transplantation.
 Experimental research was fundamental for 
the development of intestinal transplantation, including 
the evaluation of new immunosuppressant drugs. 
These studies reproduced and tried to control the main 
complications of intestinal transplantation, like the 
low period of graft preservation, graft rejection, graft-
versus-host disease, and serious infections40-58.
Experimental studies were conducted, showing 
that the strong rejection of the graft is due to high 
concentration of lymphoid tissue present in the 
intestine. After intestinal transplantation, a bidirectional 
flow of immunocompetent cells occurs between the 
recipient and the donor’s organ. This exchange 
between donor and recipient cells is a phenomenon 
known as chimerism, leading to activation of potent 
immune complexes that cause not only strong graft 
rejection but also other complications, such as 
graft-versus-host disease and lymphoproliferative 
diseases42-62.
The acute cellular rejection is frequently 
observed in intestinal transplantation and causes high 
morbidity and mortality due to the loss of integrity of the 
intestinal mucosa barrier, bacterial translocation and 
sepsis. Prevention, early identification and appropriate 
treatment are essential to control the morbidity of this 
procedure. Moreover, the strong immunosuppression 
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usually used to control rejection can cause various 
complications, such as susceptibility to infections, 
tumors and toxicity to various organs42-62. 
Using an experimental study with rats, they 
developed a new method of immunosuppression 
and immunomodulation to induce immune tolerance 
that lead to remarkable results. These patient with 
intestinal transplantation achieve better recovery, 
return to oral nutrition, improved quality of life and 
completely independence of total parenteral nutrition 
(TPN). The latest immunosuppression protocol lead 
to excellent results in intestinal transplantation, with 
significant reduction in the rate of rejection and other 
complications of immunosuppression. It is based on 
potent preoperative immunosuppression (induction) 
with high-dose antithymocyte globulin (ATG) or 
anti-CD 52 (CAMPATH), irradiation of the intestine, 
bone marrow infusion and continuous tacrolimus 
monotherapy. In clinical practice this model has been 
used without the irradiation and marrow infusion, and 
has seen encouraging results60-65.
In the laboratory of Experimental research in 
transplantation of LIM 37 of FMUSP we are currently 
researching new trends on surgical techniques, 
xenografts, rejection and preservation of intestinal 
and multivisceral transplantation42-49. 
Patient population
Intestinal Failure (IF)
Intestinal failure (IF) is defined as the 
critical reduction of functional gut mass below the 
minimal amount necessary for adequate digestion 
and absorption to satisfy body nutrient and fluid 
requirements for maintenance in adults or growth 
in children4. Fortunately, IF is relatively rare. The 
incidence in Europe is 4-6/ million, and the prevalence 
2-20/ million inhabitants.  The natural history is 
variable and is largely influenced by the underlying 
disorder. The most common type of IF is secondary to 
short bowel syndrome (SBS) after extensive surgical 
resection of the small bowel for different reasons. 
SBS is generally defined as a remnant length of 
< 150-200 cm5. 
Functional intestinal diseases, like malabsor-
ption or dysmotility disorders, can also result in IF. 
Causes of IF are multiple and differ between adults 
and children as displayed in Table 2. IF can be 
partial (patient is able to have some oral/ enteral 
intake) or total (patient fully depends on parenteral 
nutrition), and temporary (reversible) or permanent 
(irreversible).
TABLE 2. Causes of IF 






   - Hirschsprung’s disease
   - pseudo-obstruction
• inherited malabsorptive
  syndrome: 
   - tufting enteropathy 
   - microvillus inclusion disease 
   - villus atrophy 
• midgut volvulus
• mesenteric vascular thrombosis/ ischemia
• extensive surgical resection
• inflammatory bowel disease
• abdominal trauma
 • chronic intestinal pseudo-obstruction 
• (desmoid) tumor
• radiation enteritis
Total parenteral nutrition (TPN) and home 
parenteral nutrition (HPN)
Parenteral nutrition (PN) and home PN (HPN) 
is the mainstay of therapy independent of the cause 
of IF. Parenteral nutrition (PN) means feeding a 
person intravenously, bypassing the usual process of 
eating and digestion. The patient receives nutritional 
formulas containing salts, glucose, amino acids, 
lipids and added vitamins. It is called total parenteral 
nutrition (TPN) when no food is given by other routes 
in contrast to partial IF (patient is able to have some 
oral/ enteral intake). Alternatively, the degree of IF can 
be evaluated according to the amount of PN required 
for maintenance and/ or growth. PN dependence/ 
irreversibility is thought to be influenced by the 
length of remnant small bowel and the anatomy of 
the digestive circuit in SBS. Three types of SBS are 
distinguished: type 1; end-enterostomy without colon, 
type 2; jejuno-colic anastomosis with some colon in 
continuity, and type 3; jejuno-ileocolic anastomosis 
with full colon (Figure 1). 
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The length of remnant small bowel and 
preservation of the ileocaecal valve and colon 
improves oral water-mineral and energy balances. 
The anatomy of remnant digestive circuit therefore 
highly predicts reversibility of IF. Independence from 
PN can be achieved with > 40 cm in type 3 SBS, > 60 
cm in type 2 and at least 120 cm in type 1 SBS. More 
factors are being identified predicting reversibility and 
survival in IF. Clearly, in patients with a functional 
cause of IF the condition is irreversible. For example in 
(pediatric) patients with total intestinal aganglionosis, 
and in most patients with (mucosal) functional disease. 
Furthermore, abdominal wall defects are more likely 
to cause permanent IF.
In general, 3 and 5 year survival prognosis 
for IF patients treated with TPN are 86% and 75%, 
respectively. Survival is mainly influenced by the 
underlying disease. Desmoid tumor in familiary 
adenomatous polyposis (FAP), functional disorders, 
SBS with short remnant intestine (type 1 with < 50 cm 
remnant), mesenterial infarction and age (neonates 
< 1jr of age and higher age) and intestinal failure 
associated liver disease (IFALD) have a negative 
impact on patient survival.
The introduction of intravenous feeding and 
TPN in the 1960s generated a life saving treatment 
option for patients with IF. TPN allowed long term 
survival for the first time in patients with massive 
intestinal loss. Unfortunately, long-term TPN causes 
various serious complications. The permanent 
need for a central venous access catheter (CVC) 
for TPN administration exposes the patient to the 
risk of infection and/ or loss of access. The major 
parenteral nutrition related complications are blood 
stream infection (septicaemia), venous thrombosis, 
metabolic disorders (e.g. hyperglycaemia and/ or 
fluid and electrolyte dysbalance) bone disease, and 
parenteral nutrition associated liver disease (PNALD) 
as a consequence of the unphysiological nature of 
IV feeding 6. 
It must be clear that the dependency on PN 
- the inability to eat, the practical aspects and it’s 
associated complications - must have great impact on 
physical, psychosocial and social aspects of life and 
thereby can reduce the quality of life, as experienced 
by these patients7. 
Indications for ITx
HPN is still considered the primary treatment for 
chronic IF based on the comparison of relative safety 
and efficacy of both treatment options; HPN and ITx. 
Survival rates for PN therapy are superior to survival 
rates after transplantation. 
International indication criteria have been 
established, but truly, practice differs among centers 
and individual ‘patient case’ exceptions are being 
made. 
The US Center for Medicare and Medical 
Services has approved payment for ITx when HPN 
failure occurs, in view of life-threatening complications 
related to HPN8. 
Failure of HPN is defined by:
a) Impending (total bilirubine > 3-6 mg/dL, 
progressive thrombocytopenia, and progressive 
splenomegaly) or overt liver failure (portal hypertension, 
hepatosplenomegaly, hepatic fibrosis, or cirrhosis) 
because of parenteral nutrition/ IF associated liver 
disease (IFALD); 
b) Central venous catheter (CVC)-related 
FIGURE 1. Types of short bowel syndrome. From Feldman: Sleisenger & Fordtran’s gastrointestinal and liver disease. 7th 
ed. 2002. Figure 92-1, page 1808
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thrombosis of  ≥ 2 central veins; 
c) Frequent central line sepsis: ≥ 2 episodes/ 
year of systemic sepsis secondary to line infections 
requiring hospitalization; a single episode of line-
related fungemia; septic shock or acute respiratory 
distress syndrome; 
d) Frequent episodes of severe dehydration 
despite intravenous fluid in addition to HPN.
The American Society of Transplantation 
position paper on pediatric ITx also considers patients 
with a high risk of death or with high morbidity related 
to their underlying intestinal failure as candidates for 
ITx9. High risk of death attributable to the underlying 
disease is defined by: a. Desmoids tumors associated 
with familial adenomatous polyposis (FAP) b. 
Congenital mucosal disorders (eg, microvillus 
atrophy, intestinal epithelial dysplasia) c. Ultra short 
bowel syndrome (gastrostomy, duodenostomy, 
residual small bowel < 10 cm in infants and < 20 cm 
in adults).
High morbidity IF or low acceptance HPN is 
defined by: a. Intestinal failure with high morbidity 
(frequent hospitalization, narcotic dependency) or 
inability to function (eg. pseudo-obstruction, high 
output stoma); b. Patient’s unwillingness to accept 
long-term HPN (eg. young patients).
Contraindicat ions for  ITx are c lear ly 
defined10. Absolute contraindications are: a. Non-
resectable malignancy (local or metastatic); b. 
Severe immunological deficiencies; c. Advanced 
cardiopulmonary disease; d. Advanced neurologic 
dysfunction; e. Sepsis with multisystem organ failure; 
f. Major psychiatric illness; g. Demonstrated patient 
noncom-pliance; h. Insufficient vascular patency for 
central venous access for ≤ 6 months after ITx.
Relative contraindications are: a. Age older 
than 65 years; b. History of cancer in the past 5 years; 
c. Physical debilitation; d. Lack of family support.
A prospective study (11) comparing survival 
in candidates (±ITx) and non-candidates based on 
these criteria as presented above (US Medicare and 
American Society of Transplantation) confirmed HPN 
as the primary therapeutic option for irreversible IF, and 
supported the appropriateness/ potential life-saving 
role of timely ITx for patients with HPN failure. 
The low prevalence of ITx (10% in candidates, 
20% all patients on HPN for irreversible IF) reflects a 
generally reserved attitude toward ITx11.
Referral and screening
Since IF and long-term PN treatment is a 
complex and relatively rare disease condition, the 
care for IF patients should be multidisciplinary and 
specialized. Most countries have (several) intestinal 
failure centers. These centers have an IF program 
run by dedicated health professionals from different 
disciplines. Ideally such a team coordinates IF care and 
includes physicians, (pediatric) surgeons, (pediatric) 
gastroenterologists, microbiologists, nutrition specialist 
nurses, dieticians and pharmacists. 
Local primary care givers managing IF patients 
should have a close link with these specialized IF 
centers. Early collaboration should be initiated for 
any IF patient whose PN requirements are more than 
50% for at least 3 months after initiating PN. Intestinal 
failure centers, in their turn, should have close contact 
and an active collaboration with intestinal transplant 
centers for timely referral before a patient’s condition 
has deteriorated. 
The importance of timing and early referral 
is becoming more evident. Still, there are many 
unanswered questions about children and adults with 
IF and optimal timing of ITx is still unknown. Therefore, 
international recommendations state that intestinal 
failure databases should be established that can 
support multicenter studies and lead to the adoption 
of universally accepted standards of patient care with 
the goal of improving outcomes in all long-term IF 
patients including those requiring ITx10;12.
Types of intestinal transplant procedures
The small intestine (including jejunum and 
ileum) is the defining part of any intestinal transplant 
type. Intestinal failure patients with the indication 
for ITx without irreversible parenteral nutrition/ IF 
associated liver disease (IFALD) are candidates for 
an isolated (intestine-only) intestinal transplantation 
(Figure 2a). However, long-term parenteral nutrition 
has frequently caused substantial degrees of IFALD 
and is part of the indication for ITx or has developed 
after the patient has been placed on the waiting list 
for an isolated ITx. In these patients a combined 
liver-intestine transplant (LITx, figure 2b) must be 
performed. Clinically this decision remains a difficult 
one, as the exact criteria when to include a liver (for 
what degree of IFALD) remain controversial and vary 
between transplant centers. The fact that non-cirrhotic 
liver injury appears to be reversible after ITx on the one 
hand, and on the other hand a chance that preserved 
liver function may deteriorate following isolated ITx 
makes this decision even more complicated.
A combined LITx can be accomplished with a 
composite allograft or with organs separately from the 
same donor. The pancreatic head and the duodenum 
are always included in LITx to facilitate en-bloc 
engraftment and to obviate biliairy reconstruction, 
particularly in children (this is the “so called” Nebraska 
variant).
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In addition to isolated ITx and combined LITx, 
a multivisceral transplant (Figure 2c) represents 
a third type. Multivisceral transplantation includes 
transplantation of grafts of other abdominal viscera 
along with the liver and the intestinal graft. This 
may include the stomach, pancreas, spleen, and/ or 
colon. This procedure is usually reserved for patients 
with additional organ system failure (e.g. pancreatic 
insufficiency, diabetes, kidney failure), often on a 
background of a non-reconstructible gastrointestinal 
tract.
Unfortunately, there is no consensus on what 
defines a multivisceral transplant (MVTx). Sometimes 
the inclusion of the pancreas is considered to be a 
MVTx. UNOS defines a multivisceral transplant as 
one that includes intestine, liver and either pancreas 
or kidney. The international transplant registry (ITR) 
defines a MVTx as one that includes the stomach. 
The term modified multivisceral is used if the liver 
is excluded. Transplantation of the colon together 
with the intestinal allograft was previously avoided 
because of the risk of infection, but is now sometimes 
carried out13. After the transplant procedure, a feeding 
tube is inserted to provide early enteral nutrition, until 
the patient tolerates oral feeding. Some patients must 
(re)acquire feeding skills if they have not eaten for 
a long while or never learned to have oral intake. 
An ileostomy is constructed to allow surveillance 
biopsies. Graft rejection and most infections can be 
diagnosed from these biopsies. When graft function 
is stable without rejection, the ileostomy may be 
reversed. 
Postoperative care
Intensive care support of early post-transplantation 
period
Clinical monitoring and support of patients 
in the early period of post-intestinal transplantation 
must be very systematic and carried out in an 
intensive care unit. It requires frequent monitoring 
of hemodynamic and cardio-pulmonary parameters 
as well as the control of metabolic, nutritional and 
hydroelectrolytic and acid-base disorders. In this initial 
phase a high levels of immunosuppressive drugs is 
used to modulate the host immune system reaction 
against the huge immunocompetent cell population 
of transplanted intestinal graft, to avoiding rejection. 
This may cause many side effects such as renal 
dysfunction, hypertension, neuropsychiatric problems 
and infections, especially opportunistic. Furthermore, 
intestinal grafts always have injuries resulting from 
ischemia and reperfusion injury, with a potential 
occurrence of bacterial translocation66-84. 
The hormonal function of the transplanted graft 
is usually little affected in intestinal transplantation 
and hormone release mediators of vasomotor 
phenomena, such as neurotensin, serotonin, VIP and 
cholecystokinin, is conveniently maintained66-84.   
Monitoring and Control of Nutritional Support  
Within the first two week of intestinal 
transplantation there is a almost complete 
regeneration of the lymph drainage by reconstruction 
and dilatation of lymphatic vessels. However, the 
absorption of fat takes longer to be standardized, 
probably by interfering factors arising from the 
recovery of intestinal mucosa. There is also 
increasing in the total amount of lipids in the stool, 
which is reduced to the normal as soon as the 
absorption of fat is restored66-84. 
The intrinsic innervation is preserved in 
the transplanted graft, but the disconnection of 
the extrinsic innervation is strongly related to 
disorders of intestinal motility observed in intestinal 
transplantation. The graft’s extrinsic reinnervation 
process is longer, taking about 6 months to settle. 
Disconnection of the extrinsic innervation manifests 
as difficult to control diarrhea which persists for 
several months and improve after the reconstruction 
of the extrinsic innervations66-84.  
The absorptive function of intestinal graft is 
little affected. In rats with intestinal transplantation 
was observed that the weight growth curve 
was similar to that of normal animals. In clinical 
intestinal transplantation was noted that, despite 
FIGURE 2. Types of transplants
From: TM. Fishbein et al. Gastroenterology. 2003;124:1615-28.
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the slow recovery of the graft, there is progressive 
improvement of absorptive capacity, encouraging the 
discontinuation of TPN in most patients. In children, 
although small bowel transplantation promotes the 
removal of the NPT, they have growth rates below 
the normal children66-84.  
TPN is reintroduced as soon as the patient 
becomes hemodynamically stable, preferably on the 
first post-operative day. The conversion of parenteral 
nutrition to enteral or oral diet is time variable and 
occurs earlier in isolated intestinal transplantation 
fashion. Enteral feeding via jejunostomy is initiated 
after assessing the integrity of the mucosa by 
endoscopy and when bowel movement is observed, 
habitually around 7-10 days after surgery. The 
infusion is continuous and initially with low volume. 
This initial stage elemental diets or semi-elemental 
containing glutamine is preferred66-84.
With the improvement of graft function, the 
quantity and quality of food is increased until the 
patient achieves complete oral and general diet 
without supplementation by parenteral route. The 
clinical assessment of graft function is accompanied 
by body weight, height (in pediatric patients), 
urine volume, amount of drainage from the stoma, 
frequency and nature of feces and the dependence 
on TPN. Hematology and biochemistry exams 
must be performed frequently to access the 
degree of hydration, nutrition and renal function. 
Nitrogen balance and absorptive, motility and 
secretion functions of the graft must be periodically 
determined66-84.
Monitoring and Control of Rejection 
The clinical, endoscopic and histological sign 
of rejection are well defined by the literature. The 
clinical symptoms of rejection include abdominal 
pain, severe diarrhea alternating with ileus, fever, 
vomiting, malabsorption, metabolic acidosis, toxemia 
and sepsis. If there is clinical suspicion of rejection, 
the graft and the remaining recipient intestine 
should be immediately examined by endoscopy with 
multiple biopsies and histopathological examination. 
The zoom videoendoscopy which allows of up 
to 100 times magnificence allows the immediate 
identification of rejection and is a important new 
advance in this field. The overall incidence of 
acute rejection in intestinal transplantation in the 
initial series of the University of Pittsburgh was 
85%. Now with the change of immunosuppressive 
regimen combined with immunomodulation and 
preconditioning of the recipient, the rejection rates 
were significantly reduced66-84. 
Recent research shows that it is possible 
to induce specific grafts hyporeactitivty through a 
combination of intestinal transplantation with bone 
marrow infusion from the same donor. Some ongoing 
clinical protocols using strong imunossupression with 
antithymocyte globulin and tacrolimus monotherapy. 
Induction immunosuppressive therapy is carried 
out with 5-10 mg/kg of antithymocyte globulin or 
CAMPATH (anti CD 52) and 2 grams of methyl-
predinizolona5,6,23. Tacrolimus is used as the primary 
drug to prevent rejection. The dose of tacrolimus 
should be adjusted to maintain plasma levels of the 
drug between 15 and 20 ng/mL in the first 3 months, 
with subsequent reduction. After four months the 
patients without rejection episode will be considered 
to reduce the dose or administration. The treatment 
of acute rejection is achieved by steroid pulse and 
subsequent recycling (1gr EV metilpredinizolona 
followed by 200 mg the next day and subsequent 
reduction of daily 40 mg) to 20 mg / day, which 
can be reduced depending on the immunological 
outcome. In more severe cases of rejection or that 
refractory to corticosteroids, a monoclonal anti-CD3 
(OKT3), anti-thymocyte globulin (ATG) or anti-CD52 
(Campath-1H) may be used66-84.
Chronic rejection is still poorly known immune 
response, with no specific treatment and may 
cause graft removal and retransplantation, limiting 
patient survival. The grafts of isolated intestinal 
transplantation have a higher risk of acute and 
chronic rejection than grafts containing the liver (31% 
vs. 7% respectively). Other risk factors for chronic 
rejection refers to the frequency and aggressiveness 
of rejection, age (higher in adults) and race (higher 
in blacks). Tacrolimus is related to combat chronic 
rejection, but their effectiveness is limited66-84.
Monitoring and control of infections
Prevention of infection is made by large 
spectrum antibiotics (ampicillin and cefotaxime) in 
the first five postoperative days. Culture of blood, 
stool, urine, wound exudate, stoma and peritoneal 
secretion, are frequently repeated and, if positive, 
appropriate antibiotic therapy should be initiated 
according to the sensitivity of the microorganism 
found. Gancyclovir (antiviral), Bactrim (antibiotic) 
and Mycostatin (antifungal) are administered for 
prophylaxis of CMV, P. carinii and candidiasis, 
respectively. The intestine of the donor and 
recipient should be treated by decontaminating 
solution containing amphotericin B, polymyxin B and 
gentamicin. This decontamination solution should 
also be used in the rejections episodes to prevent 
serious bacterial translocation66-84.
CMV negative patients should not receive 
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grafts from CMV positive donors. This combination 
increases the incidence and severity of rejection, 
promote CMV infection difficult to control and 
lymphoproliferative diseases, affecting the graft 
and patient survival. Another important infection in 
this transplant is that caused by Epstein Barr. This 
virus interacts with the recipient’s immune system 
causing lymphoproliferative disease known as post 
transplant lymphoproliferative disease (PTLD). This 
serious condition is difficult to treat and also impair 
graft and patient survival66-84.
Outcome of ITx 
Survival, Complications and Rejection
ITx can play a potential life-saving role in 
patients with IF, if referral is timely. Multicenter 
European survival rates are 73% and 59% for 1 and 
3 year patient survival. These rates match American 
results of 79.9% and 66.1% coming from expertise 
centers where high numbers of ITx are performed.
FIGURE 3. Shows the most recent worldwide results based on the international transplant registry (ITR) as presented during 
the 11th international small bowel symposium in Bologna, September 2009.
Based on literature, both European and US 
short term survival rates are higher after ITx without 
liver (I-ITx) compared to combined intestine-liver 
transplantation (L-ITx): 73-81% for I-ITx and 0-39.1% 
for L-ITx. This possibly reflects that the patient with 
an indication for L-ITx generally has a poorer pre-
transplant condition or is referred late. The negative 
outcome of combined L-ITx emphasis the importance 
of prevention of PNALD. However, there is still ongoing 
debate whether there is a long-term protective effect 
of the liver as acute and chronic rejection rates for 
L-ITx and MVTx are lower than for I-ITx (1). Clearly, 
latest ITR results support this protective effect of the 
liver with a better long term survival for L-ITx and 
MVTx compared to I-ITx.
With the first real ‘long-term’ results becoming 
available, factors affecting survival prognosis are 
being identified. Undeniable, hospitalization seems to 
be a negative prognostic factor in patients indicated 
for ITx, also probably because of poorer clinical 
status compared to patients at home. Furthermore, 
ITx centre expertise (high numbers of procedures 
performed) positively affects prognosis.
Rejection and infectious complications are 
the main postoperative problems. Acute rejection 
occurs in 79% of patients undergoing I-ITx and is 
the leading cause of graft loss (14). Graft loss due 
to rejection is 56.3%. Other causes of graft loss are 
ischemia/bleeding/thrombosis (20.6%) and sepsis 
(8.8%). Sepsis and multi-organ failure (MOF) are the 
leading causes of death (www.intestinaltransplant.
com). Approximately one-half (47%) of deaths in 
intestinal transplant patients have been attributed to 
sepsis, while another 26% have been attributed to 
MOF to which sepsis was likely the contributing factor. 
Immunosuppression exposes the post-transplant 
patient to an increased risk for (a)typical postoperative 
infections. Furthermore, the immunogenic character 
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of the intestine - a high volume of lymphoid tissue 
in both the mesentery and the Peyer patches of 
the intestinal graft and the exposure to the external 
environment - will greatly contribute to this problem. 
Other causes of death are graft thrombosis (10%), 
post transplant lymphoproliferative disease (PTLD, 
10%), and rejection (4%). PTLD – a lymphoma that 
occurs after transplantation - is a complication of 
over-immunosuppression and is frequently associated 
with EBV infection.
Graft versus host disease (GVHD) fortunately 
occurs less frequent (0-16%) as to be expected based 
on the lymphoid nature of the intestinal graft. Strategies 
to prevent GVHD include simultaneous bone marrow 
infusion, graft irradiation and the administration 
of antilymphocyte serum. Unfortunately, GVHD is 
associated with a high mortality caused by nonspecific 
presentation and diagnostic delay.
Despite these substantial risks, post-transplant 
patient condition is quite good as the majority of 
patients has a well functioning graft and a (sub)normal 
Karnofsky score (Figure 4).
FIGURE 4. Intestinal Transplant + colon
However, the development of solutions to 
prevent rejection and infectious complication will be 
the main future target in order to improve the long 
term outcome of ITx.
In Brazil, beside the two pioneer cases of Clinic 
Hospital of University of Sao Paulo Medical school 
by Professor Okumura in the 60s, the Santa Casa of 
Sao Paulo performed a case in 2000, and the Hospital 
de Base in Sao Jose do Rio Preto Medical School 
(FAMERP) conducted three cases. The cases cited 
had limited survival in 3 cases and in one case the 
graft was removed and the patient achieved intestinal 
adaptation.
Difficulties
Clearly, this transplant type seems to be 
challenging as the success of ITx continues to lag 
behind that of other transplanted abdominal organs. 
The outcome of solid organ transplantation is highly 
dependent on the quality of the graft, placing the 
intestine at a disadvantage from the start. As a fact, 
the small bowel is the most perfused organ under 
physiological conditions, receiving up to 25% of all 
cardiac output, of which up to 90% is consumed in 
the (sub)mucosa. This physiological feature leads 
to the extreme vulnerability of the mucosal layer to 
ischemia 15. Unfortunately, a relatively long ischemic 
period bridging the gap between organ retrieval and 
implantation is insurmountable during cold storage 
(CS) during which substantial damage is encountered. 
Furthermore, brain death, surgical manipulation 
and ischemia reperfusion injury (IRI) compromise 
the mucosal barrier 16;17;17;18;18-21. This consequently 
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leads to bacterial translocation (BT) and inflammatory 
upregulation, predisposing the host to sepsis and 
rejection, the main causes of morbidity and mortality. 
Intestinal preservation
A specific limitation to successful ITx is the lack 
of a specific tailored intestinal preservation strategy. 
The current standard is a vascular flush with University 
of Wisconsin solution (UW) followed by CS in UW 
with the intestinal lumen stapled-off (closed). This 
standard is by default as a part of the multivisceral 
organ procurement procedure designed for optimal 
preservation of the liver and kidney22. Although 
UW has been established as one of the best organ 
preservation solutions (PS), this solution is unable to 
prevent substantial intestinal epithelial damage23-25. No 
single PS has proven to optimally maintain intestinal 
graft quality26-33. 
How to protect the intestine during organ 
preservation still remains an unanswered question. 
The intestine might require a tailored strategy because 
of its distinct features and extreme vulnerability. The 
development of a more effective intestinal preservation 
strategy might be essential to achieve improved long 
term results in ITx.
The intended optimal preservation strategy will 
imaginably result from a synergic effect of different 
vital essentials within a “package of conditions” that is 
yet to be defined. 
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ABSTRACT: Organ transplantation has become a substantial part of modern medicine. 
Intestinal transplantation (ITx) was introduced in the late sixties as a heroic procedure to treat 
intestinal failure. The Clinic Hospital of University of Sao Paulo Medical School is one of the 
world’s pioneer in this procedure. With the biotechnological evolution in medicine, intestinal 
transplantation emerged in the 1990s as the only curative, permanent therapeutic option for 
patients with irreversible intestinal failure. At that time, the clinical results were also disappointing 
mainly due to the high rates of post-operative infectious complications and graft rejection. 
However, the development of intestinal and multivisceral transplantation has been profound 
owing to the progress in immunosuppressive therapy, refinement of surgical techniques and 
post-transplant care. This study aims to give a general overview about when the ITx must be 
considered an option of treatment and how it must be done.
KEY WORDS: Intestines/transplantation. Parenteral nutrition. Intestines/pathology.
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